Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges ahead for trials in Friedreich's ataxia.

The Lancet. Neurology - 1 Dec 2016

Lynch David R, Kichula Elizabeth

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Friedreich Ataxia
Share to Phenotype
Share to Trinucleotide Repeats

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 27839636
DOI: 10.1016/S1474-4422(16)30281-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges ahead for trials in Friedreich's ataxia.PMID 27839636Read ↗

Lessons for clinical trial design in Friedreich's ataxia.Semantic proximity Read ↗

Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome.Semantic proximity Read ↗

From Genetic Mutation to Therapy in Friedreich Ataxia: Molecular Mechanisms, Therapeutic Advances, and Translational ChallengesSemantic proximity Read ↗

Milestones in Friedreich ataxia: more than a century and still learningSemantic proximity Read ↗

From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to TranslationSemantic proximity Read ↗

Friedreich ataxia.Semantic proximity Read ↗

Advances in Gene and Cellular Therapy in Friedreich Ataxia.Semantic proximity Read ↗

Friedreich's ataxia: new insightsSemantic proximity Read ↗

Preclinical alternative drug discovery programs for monogenic rare diseases. Should small molecules or gene therapy be used? The case of hereditary spastic paraplegiasSemantic proximity Read ↗

A Pilot Phase 2 Randomized Trial to Evaluate the Safety and Potential Efficacy of Etravirine in Friedreich Ataxia PatientsSemantic proximity Read ↗

Moving towards clinical trials for mitochondrial diseases.Semantic proximity Read ↗

Challenges of clinical trial design for DMD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.